HSIE Results Daily: Dr Reddy’s Laboratories, Supreme Industries, Dalmia Bharat...
Dr Reddy’s Laboratories: EBITDA^ declined 11% YoY due to moderate sales growth of +4% YoY (as 10% QoQ decline in the US on lower gRevlimid sales...
192 Views
Pharmaceuticals: IPM: strong 15% growth in Dec-25
Growth was led by CVS, anti-diabetes, CNS, and oncology segments, while growth in anti-infective, gastro, respiratory, and pain grew at par or...
183 Views
Pharma and Healthcare (Q3FY26E Results Preview): Base business momentum to offset gRevlimid drag
The India Pharma and Healthcare sector is expected to see moderate revenue growth as EBITDA margins remain flat. We project sales/EBITDA growth of...
189 Views
Pharmaceuticals: IPM: growth recovers to 11.7% in Oct-25
In chronic space, cardiac continues to drive IPM growth in Oct-25 at 17% YoY (+11% in Q2FY26), anti-diabetic at 15% (+9% in Q2FY26), led by...
191 Views
Pharmaceuticals: IPM: grows 6.1% in Sep’25 and 7.2% in Q2FY26
The strong growth in cardiac, respiratory, and oncology was offset by muted growth in anti-infective, gastro, VMN, and pain. For Q2FY26, IPM grew...
259 Views